Zenith to reach new heights with expanded reach in the U.S.

Ireland-based life science tech services firm Zenith Technologies is boosting its U.S. presence with two new offices on the West Coast.

In a statement, the Cork-headquartered company said it was expanding its global footprint as a result of “greater demand for its automation, process control and serialization technology support services.”

Zenith, which has been in the U.S. for a decade since the opening of its first American site in Pennsylvania, will now look west with its latest offices in Oakland and San Diego.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The idea is for the firm to deliver a more localized service to its North American customers, the company said, which include small and mid-sized pharma and biotech companies as well as CMOs and Big Pharma firms.

Mike Smith, U.S. sales manager at Zenith Technologies, said: “We are looking forward to bolstering our US presence with the opening of these two new sites as it means we can provide complete coverage of service in the US from coast to coast.

“Expanding into such high growth areas for the life science and biotechnology industry means it is a really exciting time for our company and a great way to mark a decade of presence in North America.”

Both offices are designed as a hub to help the company with its ongoing projects, as well as for back office assistance and managed services.

- check out the release

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

The Mayo Clinic tapped data analytics firm nference to build out an AI-powered engine to collate its years of clinical records and pathology work.

At the annual J.P. Morgan Healthcare Conference, major CRO Charles River Laboratories and Takeda announced a new preclinical tie-up.